Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
株式のランク #39071
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
株価
$0.0568
最終同期: 2026-08-13
時価総額
$661.36K
変化(1日)
11.37%
変化(1年)
-5.33%
US
取引 Hepion Pharmaceuticals, Inc. (HEPA)

カテゴリー

Hepion Pharmaceuticals, Inc.(HEPA)のP/S比率
2026 時点のP/S比率 TTM: 0
Hepion Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
Hepion Pharmaceuticals, Inc. の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率